Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.

Pharmacogenetics and genomics - 1 Oct 2015

Mirzakhani Hooman, van Dormolen Juliët, van der Weide Karen, Guchelaar Henk-Jan, van Noorden Martijn S, Swen Jesse

Abstract excerpt

We investigated the accumulation of aberrant CYP2D6 genotypes and predicted metabolizer phenotypes (ultrarapid metabolizer, intermediate metabolizer and poor metabolizer) potentially affecting the antidepressant treatment response in depressive patients indicated for electroconvulsive therapy (ECT) compared with patients with a single episode of depression. Seventy-six Dutch White patients with unipolar or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antidepressive Agents

Share to Cytochrome P-450 CYP2D6

Share to Logistic Models

Share to Multivariate Analysis

Share to Phenotype

Source

Identifiers

PMID: 26230381
DOI: 10.1097/FPC.0000000000000167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.PMID 26230381Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group.Semantic proximity Read ↗

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.Semantic proximity Read ↗

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Semantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

[Clinical interest of CYP2D6 genotyping to treat depression in practice].Semantic proximity Read ↗

Exploring the role of drug-metabolising enzymes in antidepressant side effects.Semantic proximity Read ↗

The impact of CYP allelic variation on antidepressant metabolism: a review.Semantic proximity Read ↗

Do we need pharmacogenetics to personalize antidepressant therapy?Semantic proximity Read ↗

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.Semantic proximity Read ↗

Antidepressant Treatment and Altered CYP2D6 ActivitySemantic proximity Read ↗

Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.